首页> 外文期刊>Endocrine-related cancer >Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells
【24h】

Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells

机译:LY294002,Akti-1 / 2和雷帕霉素在甲状腺细胞中对碘化钠同向转运蛋白的表达和功能的调节

获取原文
       

摘要

The selective increase of Na+/I? symporter (NIS)-mediated active iodide uptake in thyroid cells allows the use of radioiodine I131 for diagnosis and targeted treatment of thyroid cancers. However, NIS-mediated radioiodine accumulation is often reduced in thyroid cancers due to decreased NIS expression/function. As PI3K signaling is overactivated in many thyroid tumors, we investigated the effects of inhibitors for PI3K, Akt, or mTORC1 as well as their interplay on NIS modulation in thyroid cells under chronic TSH stimulation. PI3K inhibition by LY294002 increased NIS-mediated radioiodide uptake (RAIU) mainly through upregulation of NIS expression, however, mTORC1 inhibition by Rapamycin did not increase NIS-mediated RAIU despite increased NIS protein levels. In comparison, Akt inhibition by Akti-1/2 did not increase NIS protein levels, yet markedly increased NIS-mediated RAIU by decreasing iodide efflux rate and increasing iodide transport rate and iodide affinity of NIS. The effects of Akti-1/2 on NIS-mediated RAIU are not detected in nonthyroid cells, implying that Akti-1/2 or its derivatives may represent potential pharmacological reagents to selectively increase thyroidal radioiodine accumulation and therapeutic efficacy.
机译:Na + / I的选择性增加? Symporter(NIS)介导的甲状腺细胞对碘的吸收使放射性碘I131可用于甲状腺癌的诊断和靶向治疗。但是,由于NIS的表达/功能降低,在甲状腺癌中NIS介导的放射性碘积累通常会减少。由于PI3K信号在许多甲状腺肿瘤中被过度激活,因此我们研究了PI3K,Akt或mTORC1抑制剂的作用,以及它们在慢性TSH刺激下对甲状腺细胞中NIS调节的相互作用。 LY294002对PI3K的抑制作用主要是通过上调NIS的表达来增加NIS介导的放射性碘的摄取(RAIU),但是,尽管NIS蛋白水平升高,雷帕霉素对mTORC1的抑制作用却不会增加NIS介导的RAIU。相比之下,Akti-1 / 2对Akt的抑制作用并未增加NIS蛋白的水平,但通过降低碘的流出速率和增加NIS的碘化物转运速率和碘亲和力,显着增加了NIS介导的RAIU。在非甲状腺细胞中未检测到Akti-1 / 2对NIS介导的RAIU的影响,这表明Akti-1 / 2或其衍生物可能代表了选择性增加甲状腺放射性碘蓄积和治疗功效的潜在药理试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号